Neuroscience

Neuroscience Antibodies and Assays Market Size, Analytical Overview, Growth Factors, Demand, and Forecast to 2027 – Cheshire Media

What are the emerging opportunities in the Neuroscience Antibodies and Assays Market?

Currently, significant business sectors are going through changes. This has prompted huge benefits for a few and misfortunes for other people. To make the most out of the emerging chances, you can exploit the most granted Neuroscience Antibodies and Assays market report. It offers nitty-gritty experiences into the market. This will doubtlessly manage their organizations in creating the following move over the impending industry quarters.

It must be noticed that the Neuroscience Antibodies and Assays market is encountering unexpected ascent in reception by numerous new players (from MNCs to SMEs). It is because of the way that even with the market turbulences the Global market came out with solid numbers. With the new business running into the market, it is basic to stand apart from the group. The customers can undoubtedly accomplish this utilizing the means referenced in the Neuroscience Antibodies and Assays market report.

What type of investigation is done in the Neuroscience Antibodies and Assays market report?

Analysis of various socioeconomics for venturing into the market is important as it will hugely affect the development throughout the following coming years. The Neuroscience Antibodies and Assays market report is planned subsequent to doing long periods of exploration and the information sifted through in the report was gathered from dependable sources, for example, government sites.

As the market is gigantic, it turns out to be imperative to comprehend the market from its underlying foundations. Get a superior perspective on the Neuroscience Antibodies and Assays market through the data referenced in the committed areas of the report. With this, the customers likewise get a perspective on the business structure of the contenders.

What are the reasons that impact the growth of the Neuroscience Antibodies and Assays Market?

As of late, the advanced transformation has pushed the associations in changing into a computerized business for coming to the intended interest group present over the globe. The Neuroscience Antibodies and Assays market report shares the significance of neighborhood language, partners, and political situation that will drive the Global market higher than ever.

With the best possible comprehension of the Neuroscience Antibodies and Assays market, the associations can hop onto the open doors that will bring productive outcomes. The customers can exploit the biggest in-house information base for taking the most effective actions. Likewise, the Neuroscience Antibodies and Assays market report has committed segments covering the insights concerning the current market players. With the information on how they function and accomplish their objectives, your business can likewise be formed as needs be.

What type of analysis short-term or long-term is added in the Neuroscience Antibodies and Assays Market report?

This is important to sidestep any negative circumstances that may affect the development of the organizations. In addition, the associations need to comprehend Porters five powers that shape the market elements. In the event that the customers wish to add or eliminate the names of the organizations, it tends to be done, to suit the desires for the clients, for accomplishing long-haul objectives. SWOT investigation helps in uncovering the qualities and shortcomings of the business. The PESTLE investigation helps in checking the outer elements that shape the market overall. Subsequently, for making a name in the Neuroscience Antibodies and Assays market, it gets important to get thought from both SWOT and PESTLE investigations.

The Neuroscience Antibodies and Assays market report likewise brushes over the significance of language and partners for the smooth working of the associations. Thusly, the customers are stacked with data and steps and are prepared to move into the market for accomplishing the ideal objectives.

About Us:

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Reports provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Original post:
Neuroscience Antibodies and Assays Market Size, Analytical Overview, Growth Factors, Demand, and Forecast to 2027 - Cheshire Media

Neuroscience

Researchers receive $651,997 funding to study memory dysfunction in MS – News-Medical.Net

Researchers at Montclair State University and Kessler Foundation have received funding totaling $651,997 from the National Multiple Sclerosis Society to measure memory-related abilities in individuals with and without multiple sclerosis (MS) for clues to how such cognitive processes are altered by MS. Joshua Sandry, PhD, assistant professor of psychology at Montclair State and Ekaterina Dobryakova, PhD, research scientist in the Center for Traumatic Brain Injury Research at Kessler Foundation, collaborate on the 4-year study, titled "Neuroimaging of Hippocampally Mediated Memory Dysfunction in Multiple Sclerosis."

Dr. Sandry, director of the Cognition and Neurocognitive Disorders Research Laboratory, at Montclair State, is principal investigator for this project. Dr. Dobryakova will oversee the clinical study, including advanced neuroimaging studies performed at the research-dedicated Rocco Ortenzio Center for Neuroimaging at Kessler Foundation.

Memory problems are a common cognitive disability that negatively affect the quality of life of individuals with MS. Despite the urgent need to develop effective treatments, this challenge has been met with mixed success. Lack of knowledge about the underlying cognitive and brain processes responsible for memory problems in MS hinders clinical progress.

This study aims to translate research from cognitive neuroscience to the MS research community to help identify which underlying cognitive and brain processes are impacted by MS. Specifically, researchers will investigate how changes in working memory and structural changes in the hippocampus may contribute to the memory problems that affect individuals with MS.

To our knowledge, this is the first investigation to utilize a strong translational approach to begin to pinpoint the interrelationship of working memory, brain functioning, and long-term memory problems in MS. This cutting-edge research may provide a strong foundation to our understanding of memory loss, and lead to effective interventions for restoring lost function."

Dr. Ekaterina Dobryakova, PhD, Research Scientist, Center for Traumatic Brain Injury Research, Kessler Foundation

Go here to see the original:
Researchers receive $651,997 funding to study memory dysfunction in MS - News-Medical.Net

Neuroscience

To Convince Vaccine Skeptics, Use Empathy, Information and a Re-Start, Experts Say – Duke Today

DURHAM, N.C. With multiple COVID-19 vaccines on the way in the United States, public health officials now face the daunting challenge of convincing skeptics to actually get the vaccine.

Three Duke experts in public health messaging, leadership and human behavior spoke with journalists Thursday in a virtual media briefing about challenges and solutions.

Replay the briefing on YouTube.

Here are excerpts:

ON REACHING PEOPLE WHO DONT FOLLOW PUBLIC HEALTH RECOMMENDATIONS

Dan Ariely, psychologist, behavioral economist

Doing something now, after a really, really long time of not doing a lot, is not easy. We have to work against a lot of forces. The first thing we need to do is put a time separation between the past and between the future. Theres lots of negative trends in life. Theres not upward trends. If we want an upward trend, what we need to do is stop, reflect and start fresh. Think of something like the Day of Atonement, or the Catholic confession. We need to create a new contract.

If you think about peoples personal experience, it would basically teach us that its not a good idea to follow the guidelines. Think about something like texting and driving. Imagine if you think to yourself the probability of texting and driving and something bad happening is 1 percent. So one day you drive and youre tempted by your phone, and you text, and nothing happened. So you update your belief and say maybe its not one percent, its more like .75 of a percent.

COVID-19 is a terrible tragedy but on an individual level, if you one day walk without a mask, or youre not careful and nothing bad happens to you, you learn the wrong lesson and you learn it again and again. Its a low probability event. So we need very different tools. We cant hope that peoples personal experience will teach them this is a good idea.

We need social understanding that this is the right behavior. We need people to say to each other, Im sorry, I dont feel comfortable. Would you mind putting a mask on? It has to be friendly enforcement of everything we do.

ON WHAT MESSAGING WORKS, WHAT DOESNT

Gary Bennett, professor of psychology and neuroscience

Browbeating doesnt work. Its also not useful to imagine that all of the kinds of change were trying to promote is within the control of the individuals. Organizations, leaders have a role to put together policies and systems and structures that will make it easier for individuals to adhere to recommendations.

There is a widespread perception that education is a cure-all. If we just told people more about the condition, if we just helped them understand how significant an event this is, they would change. That kind of notion doesnt work.

We want to do a lot less telling people what to do, and show them examples of how they can do it. It really starts with leaders; its really critical they model the types of recommendations theyre making.

If youre a business leader, having your handwashing stations, having your sanitizing stations, having a testing protocol, those are all really critical components.

Id argue we also have to have empathy for the complexity of this moment.

What we aspire to is a world in which everyone feels theyre doing the right things by following the guidelines. Thats about having very clear goals and being very consistent with them. Be really, really careful to encourage people and not to browbeat them when they have not adhered.

ON THE IMPORTANCE OF HIGH VACCINATION RATES

Lavanya Vasudevan, assistant professor of family medicine and community health

In my opinion, our best hope of getting the pandemic under control is to get high rates of vaccinations. Vaccines arent going to be our only way out of this pandemic, but I definitely believe they will be a very important component.

Public health is all about collective action. There is no public in public health without public participation.

Having effective vaccines like we have right now are critical. But vaccines themselves dont save lives; vaccinations do.

We need to focus all our efforts on doing everything we can to get people vaccinated. My hope is that as the vaccination campaigns unfold in the UK, Canada and here in the U.S., we will see the vaccine acceptances go up. Theres no excuse for losing more lives to this pandemic once we have an approved vaccine.

ON THE BEST VACCINE PUBLIC RELATIONS CAMPAIGNS

Lavanya Vasudevan

The two things that come up are the need for information and the need for trust. Information alone is not enough; it is important that the information has certain characteristics. The more personalized information is, the more it answers the questions that people have, as opposed to it being generic, (the better it is.)

Who is providing that information? If you just have information coming from a source you dont know or trust, that information is not going to go very far.

Gary Bennett

Vaccine hesitancy is going to be a primary risk factor for COVID deaths in the next year. This is one of the most important public health challenges for our time.

For me, the mistrust is a primary challenge that were going to be dealing with. The reasons for mistrust vary considerably across the population. They happen to be particularly high in populations that have the highest rates of COVID. So it would be a mistake to imagine a kind of one-size-fits-all public service campaign as a solution. It will take a much more nuanced strategy.

ON ONE WAY TO MAKE IT EASIER TO BE VACCINATED

Dan Ariely

If I could design a system to increase vaccination, one of things Id change is, Id change the default. Right now when you wake up in the morning, the default is that youre not vaccinated and you need to do something to get vaccinated. This creates a bias against doing it. I would love to schedule for each citizen an appointment for vaccination. Id still allow the citizen to opt out. But instead of saying, I want in, they can opt out. Thats a shift in the way of thinking about this. I think more people would get vaccinated. The systems we create are incredibly important. Is it the easiest thing to do to get vaccinated?

So here we need to say, How do we make it public? How do we make it visible? How do we make it the default?

ON REBUILDING TRUST IN GOVERNMENT

Dan Ariely

Trust is one of those things that allow us to collaborate. If I think other people are not going to adhere to the COVID rules, I dont have a reason to do it as well. Its only if everybody does it that we all have the benefit.

I think a new president can get us to start a new contract with the government, basically saying lets start fresh from now. Here are the rules. That president will also have .... to say, I will communicate when things will go well and when things dont go well.

We can have a new contract, but it cant be an empty promise. It has to be something with some power behind it.

We need better explanations for what the science is. Some people are afraid of injections. What is this material that comes in? Theres all kinds of conspiracy theories around. I think we need to calm people down. Maybe we need to take this fear seriously, with respect, and explain what is an RNA-based vaccination? What does it look like? How does it work? What is the mechanism? We cant do a Ph.D. in biology but maybe we need to work a little bit on helping people understand what this is all about.

ON EMPATHY FROM LEADERS

Gary Bennett

I think its critically important. An essential human need is to be seen and heard and understood. When leaders demonstrate that with their words, its an essential building block in establishing trust.

The challenge for leaders now is being vulnerable enough and wise enough to do the hard work of really understanding some of the reasons for the mistrust and how they may vary among different groups.

My recommendation to policymakers at moments like these is to really spend some time listening intently to various constituencies.

ON LEADERS ADDRESSING VACCINE UNCERTAINTY

Gary Bennett

The first thing is certainly not to try to be all-knowing. That generally fails. This is a critical challenge for most organizations at most times. Its particularly true right now.

Frequent communication is absolutely critical, and the nature of that communication is critically important. Communication from leaders to others that is authentic, that is transparent as possible, that demonstrates empathy and knowledge is really important.

One way of countering uncertainty is to provide certainty where certainty can be provided. Communicating what we know on a relatively expected and pre-defined timeline is really important.

The challenge for leaders in moments of uncertainty is that trust is in short supply. The return on investment for frequent communication is only realized at some point far in the future.

Lavanya Vasudevan

Trust cannot be earned overnight. It really takes long-term effort, building relationships to build trust.

ON US VACCINE CAMPAIGNS AND DENIALISM

Lavanya Vasudevan

We have the added challenge of being in a highly partisan environment, but I would argue that is not unique to the U.S. You see that in other parts of the world as well. In terms of what we need to communicate, this tailoring and personalization is extremely important.

We are seeing this huge wave of denial. Even though there were 3,000 deaths yesterday, there are huge numbers of people out there saying there is no COVID-19.

This is one of the issues weve had in this COVID-19 pandemic in general. We have made tremendous scientific progress given we knew nothing a year ago. But there are still gaps in information, and what happens when you have gaps, those gaps get filled in with things other than science. You have misinformation, myths. And when you have something in place, its harder to dislodge that and replace that with science and facts.

ON CREATING VACCINE DEMAND

Dan Ariely

I think we should use the scarcity as a way to create motivation. Im imagining that we have a wait list. We let everybody sign up and wait. Even if 58 percent of people sign up, there will be a long wait list. It will look like everyone wants this.

ON CONCERNS ABOUT LONG-TERM VACCINE EFFECTIVENESS

Lavanya Vasudevan

With the number of deaths we have had over 3,000 yesterday even a vaccine that offers short-term benefits is worth it. Thats something we need to communicate. If it turns out the immunity is just going to last for a year and well have to re-vaccinate, well figure out a way to do that.

ON SKEPTICISM OF HOW FAST VACCINES WERE CREATED

Gary Bennett

Weve gone from the bliss of a year ago to having a vaccine in a year. It only makes sense that people would imagine theres something wrong with the speed of that timeline.

The fact is, weve known how to create these vaccines for quite a long time. The U.S. government invested a ton of money in providing readiness to be able to stand up vaccines like this.

Messaging that kind of thing now is unlikely to be heard in the way we would hope it to.

My concern is that in the politically fraught environment in which we live, its been impossible to describe the response, the public/private partnership that has resulted in these vaccines in the way that we should. Its on the order of the kinds of public works projects we saw in World War II.

Its a fairly amazing undertaking. Its been challenging to describe. I hope that changes.

Dan Ariely

People think of it as a year. Its not a year. Its been an ongoing effort for a very long time.

I think science has (not) done a good job of promoting science. I think we should have had a celebration of all the people working so hard for such a long time to find solutions. Its a great history of people working unbelievably hard to try to figure this out.

So its not true to think of it as a year. Its a breadth of effort.

ON POLITICAL LEADERSHIP

Gary Bennett

We had a moment back in February/March where there was a pretty good chance that we could have significantly curtailed this pandemic. There are some arguments that say that President Trump is one of the few people who probably could have gotten it done in some respects because he could have spoken to a group of people who are particularly disaffected and less historically likely to (listen) to government messages.

We have another chance coming now with the vaccine. Its the kind of thing that should be unifying to some degree really across this politically fraught divide we have right now.

Its going to require really deft leadership that isnt focused exclusively on hogging the mic at all times.

ON WHAT YOUD SAY TO A FRIEND WHOS UNSURE ABOUT VACCINE

Dan Ariely

I would say I think theres no chance they will regret it, but, if they dont take it they are either going to get sick or get other people sick, and they could regret it. I would ask them to imagine how they would feel if they passed COVID-19 to someone else. Just try to imagine how that would feel. Now tell me you shouldnt do a lot to prevent that terrible feeling of regret that you didnt take the vaccination earlier.

Gary Bennett

I usually ask people to get three people in your mind, over age 60, people you care about now imagine that you have the ability to keep them from getting this disease. Help me understand why you wouldnt choose to do the right thing. For me, this is about the communal impact and helping people to understand that even if youre in a very low risk group, the decisions they make have potentially significant impacts.

Lavanya Vasudevan

I would actually try to understand what their positions on vaccines are and what their concerns are and try to respond to that directly.

Faculty Participants

Dan ArielyDan Ariely is a professor of psychology and behavioral economics at Duke, and a founding member of the Center for Advanced Hindsight. He studies the irrational ways people behave and designs ways to make human behavior more rational.

Gary BennettGary Bennett is a professor of psychology and neuroscience, global health and medicine at Duke University. He directs the Duke Global Digital Health Science Center and is also president of the Society of Behavioral Medicine.

Lavanya VasudevanLavanya Vasudevan is an assistant professor in the Department of Family Medicine and Community Health and the Global Health Institute at Duke. She is also a faculty affiliate at Dukes Center for Health Policy and Inequalities Research.

Duke experts on a variety of other topics related the coronavirus pandemic can be found here.

###

Continued here:
To Convince Vaccine Skeptics, Use Empathy, Information and a Re-Start, Experts Say - Duke Today

Cell Biology

Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced its launch and Series A financing of $81 million. Faze is founded by leading experts in the emerging field of biomolecular condensates with the mission of leveraging this fundamentally new understanding of cell biology to develop therapies to slow, halt or reverse disease pathology. The Series A was led by Third Rock Ventures with Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments participating.

Biomolecular condensates are membrane-less clusters of molecules, such as proteins and nucleic acids, that dynamically organize to perform a wide array of cell functions. Research over the past decade, including seminal work by Fazes founders, has found that disturbances in the behavior of condensates play a causative role in myriad human diseases, including amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Faze is now poised to deliver medical breakthroughs based on this fundamentally new understanding of cell biology.

The biology of condensates is the kind of science that will rewrite textbooks and, we believe, rewrite medicine, said Cary Pfeffer, M.D., interim chief executive officer of Faze and partner at Third Rock Ventures. Faze is founded by leading experts who have been integral to this field since its very beginnings. Their insights, coupled with the deep expertise of the team we have assembled, will enable us to realize the enormous potential of this new biology.

Cell biology is undergoing a transformation as we come to understand the integral role that biomolecular condensates play within cell processes from DNA repair to intracellular transport, added Rachel Meyers, Ph.D., chief scientific officer of Faze. Faze was founded to translate these exciting discoveries out of the lab and into the clinic, where they could make a real difference in treating diseases that have seen very little therapeutic progress.

The Series A will support Fazes preclinical research in two initial therapeutic focus areas ALS and myotonic dystrophy type 1 (DM1) as well as research to explore condensate biology in other disease areas. In ALS and DM1, a robust body of literature points to a causative role for condensate dysregulation. Leveraging state-of-the-art screening and proteomics techniques, Faze will identify proteins that are key components or regulators of disease-causing condensates, and then employ proprietary assays to discover small molecule drugs targeting these proteins.

Founders and Leadership

Faze is founded by renowned scientific leaders in the field of biomolecular condensates:

Fazes leadership team brings together accomplished biotechnology executives with decades of industry experience and deep scientific, drug discovery and drug development knowledge:

Joining Dr. Pfeffer on the companys inaugural board of directors is:

Faze has additionally established a robust group of expert advisors including those in the areas of drug discovery and clinical development.

About Faze Medicines

Faze Medicines is a biotechnology company harnessing the groundbreaking new science of biomolecular condensates to create medical breakthroughs. Faze was founded by renowned scientific leaders in the field of biomolecular condensates and is supported by a world-class syndicate of investors including Third Rock Ventures, Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments. For more information, visit fazemed.com.

See the original post here:
Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease - Business Wire

Cell Biology

New Worthington Enzyme and Biochemical Product Catalog Features Solutions for Life Science Research and Bulk Requirements – Newswise

LAKEWOOD, NJ (December 9, 2020) Worthington, the leading supplier of specialty enzymes for over 70 years, announces today the publication of an expanded, 2021-22 Enzyme and Biochemical Product Catalog. As a primary enzyme producer for biochemistry, cell biology, molecular biology, pre-clinical research and bioprocessing applications, Worthington is the go-to expert in enzyme technology.

Even with COVID restrictions in place, Worthington employees have been diligently working to support our customers needs, said Jim Zacka, vice president at Worthington. Releasing a number of new products this year, we continue our legacy of advancing research through innovation in enzyme development for both research, OEM and bioprocessing customers.

The new catalog is available in two easy-to-use formats, a downloadable PDF and an easy-to-navigate, digital catalog for online browsing and purchasing.

To request a PDF, go to: Worthington-Biochem.com

About Worthington Biochemical Corporation

Founded in 1947, Worthington Biochemical Corporation is an industry leader in the development and production of high-quality purified enzymes, proteins, nucleic acids and cell isolation kits for life science research, diagnostics and biotechnology applications. An ISO9001 Certified, primary manufacturer Worthington meets enzyme requirements from research to scale-up bulk bioprocessing and OEM applications. Products extensively cited in peer-review journals and open-access publications, the company is committed to supporting STEM education. Worthington Biochemical Corporation is a privately held company, headquartered in Lakewood, NJ and has worldwide distribution through a network of exclusive distributors.

Go here to see the original:
New Worthington Enzyme and Biochemical Product Catalog Features Solutions for Life Science Research and Bulk Requirements - Newswise

Cell Biology

Repair protein may prevent damage to healthy cells during cancer therapy – News-Medical.net

A key way radiation therapy and chemotherapy work is by making highly lethal double-strand breaks in the DNA of cancer cells. A Georgia Cancer Center scientist wants to help those therapies work better by better understanding the complex DNA damage repair process, because sometimes these therapies can inadvertently contribute to cancer.

We are trying to identify a repair protein that can help healthy cells avoid dying or becoming cancerous."

Dr. Chunhong Yan, Molecular Biologist, Cancer center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University

ATF3, a sensor of cell stress which Yan's team has shown is an early and important player in DNA damage repair, may be that protein. A new $1.7 million grant (R01CA240966) from the National Cancer Institute is helping them find out.

Our hereditary material is contained in the nucleus of our cells, and is constantly bombarded by factors like sunlight and oxidative stress, even chemicals in our food. Our healthy cells are mostly adept at DNA damage repair, but cancer cells have a defect in their DNA damage repair mechanism that should leave them more vulnerable to chemotherapy and radiation. In fact, our healthy cells' natural, rapid ability to repair DNA damage is considered a natural cancer barrier because incomplete repairs can accumulate and become cancer, Yan says. That's one of the reasons cancer risk generally increases with age.

One of the problems with radiation and chemotherapy is the collateral damage it does to healthy cells. Despite efforts at more targeted delivery, the treatments also can produce serious, double-strand breaks in the DNA of healthy cells, putting them at risk of dying or becoming part of the tumor, one of the unfortunate side effects of these therapies and key reasons for Yan's interest. "If we can find something that specifically only kills cancer cells, but keeps normal cells healthy, that could be very beneficial to patients," he says.

So Yan and his lab are dissecting this important "genome maintenance" of DNA repair. If their findings continue to hold, their ultimate goal is new cancer therapies that make increased use of the ATF3's skill at stopping spontaneous tumor production.

They have already shown that the protein ATF3 is essential to efficient, complete access to DNA and its repair. That without it mice get more tumors, which suggests that ATF3 is important in suppressing tumor formation, he says. That includes establishing a direct link between ATF3 and the established tumor suppressor p53. They found ATF3 can bind to p53 and increase expression of this protein which also has a role in DNA damage response, including going to the scene and putting the cell in a state of rest to ease repair. The other side of the coin is that when a cell can't repair, p53 enables it to commit suicide. Without ATF3, there is a better chance the cell will just become cancer, Yan says.

But good repair first requires access. To get our long DNA to fit inside our compact cells, proteins called histones provide a sort of spool, called a nucleosome, around which the iconic double-stranded DNA is wound. Chromatin is the biological packaging. In the snug confines of chromatin, the familiar classic double helix that resembles a twisted ladder is more of an X-shape resembling a clothespin.

When a cell senses DNA damage, the histones need to modify the chromatin so repair proteins can get inside and do their work and the DNA needs to relax its grip on the nucleosome. One they gain access to the damage, repair proteins enable what is called non-homologous end-joining by essentially trimming the broken ends of the damaged DNA and patching them back together.

Yan is learning more about those modifications to the histones and the ones needed to recruit those repair proteins, which already are in the nucleus, right to the damage site.

Their goals including learning more about how ATF3, also already present in the cell nucleus, gets to the actual DNA damage site. They have evidence that yet another histone, called H2AX, may be part of that.

H2AX is in the chromatin, and when there is a double-strand break in the DNA, it gets modified within seconds into? H2AX, which Yan's lab has evidence recruits ATF3 to the damage site. Yan notes that while he cannot yet say that these are the first changes, he can say they are very early ones.

"What we have found is ATF3 can come to the damage site pretty quickly, and promote the chromatin change," Yan says. They've found ATF3 binding to and stabilizing the enzymes Tip60 and p300/CBP can help provide direct access to the DNA damage site so repair proteins can move in.

This so-called histone acetylation is considered a principal way DNA damage repair happens, so identifying the genes that regulate this important intersection so that cells can be properly repaired and avoid becoming cancerous is important, Yan says.

Yan's lab has shown that ATF3 can activate the natural tumor suppressor p53 while getting Tip60 to activate the major DNA damage response kinase ATM, which provides a sort of framework for the team of repair proteins that will be recruited. p53 also is an early arriver, like a master engineer, helping make decisions on whether or not the DNA is a loss or can be repaired.

Now they want to learn more about how ATF3 promotes p300/CBP that ultimately brings on multiple repair proteins. That includes learning more about how ATF3 alters chromatin's structure to help recruit these repair proteins. A mouse missing ATF3 is enabling them to better see the roles of ATF3 including exploring further whether cancer increases when it is MIA.

Yan has documented lower ATF3 levels in people with cancer; and how taking down ATF3 levels decreases DNA repair and increases susceptibility to radiation. His research team also has found ATF3 is important in stopping damaged cells from becoming cancer. Yan and others additionally have shown that ATF3 can suppress spread of lung, colon and bladder cancers.

DNA damage is one of the most common sources of cell stress.

Like many body functions, the DNA repair mechanism tends to get less efficient with age. DNA damage, unrepaired or incompletely repaired, can lead to mutations, which increase the risk of the cell becoming cancer; or, with the help of p53, cell death from apoptosis, the innate ability of a cell to kill itself, when an injury likely cannot be repaired.

Read the original:
Repair protein may prevent damage to healthy cells during cancer therapy - News-Medical.net

Cell Biology

Cell Biology, Molecular Biology, Biotechnology And The Man Who Is Connecting It All: Felix Paul Joe – Outlook India

Thats the philosophy of Felix Paul Joe and preferably the biggest explanation one can have for his unflinching crusade in the field of biotech research. Felix founded GeneX India Bioscience Pvt. Ltd. in 2004 but, the journey before it prepared him for everything that came next.

After earning a Masters in Life Science and Post Graduate Diploma in Business Administration from the University of Madras and Madras Productivity Council, Felix was all set to create his own path in biotechnology. But, revolution is a way paved stone by stone. Before realizing his passion and dream to become an entrepreneur, Felix completed a nine-year run in different biotech companies. As a National Sales & Product Manager, he embarked on a journey that shaped his understanding of what the industry is and what it needs.

He attended a plethora of application training on varied subjects like molecular biology, cellular microscopy, interphase chromosome profiling and Proteomics. His learnings from these teachings formed a crucial part of his ventures growth model in the later years. He also completed exclusive product training and lab sessions at many international labs and forums during his days as a manager. Working with many Centres for Excellence labs across India, Felix perceived the need for a bridge between the Indian and global standards.

In 2004, when Felix established GeneX India Bioscience, the company only started as a distributor of cell culture products. Molecular biology and biotechnology were then added to widen the spectrum. Today, the company focusses in the fields of bio-science research institutes, molecular diagnostic labs, biopharmaceutical R&D, biotech contract research and development centres.

Over the years, the organization created a line of products and solutions, namely Cell Biology, Real-Time PCR, Epigenetics, Next Generation Sequencing and Protein Biology. The private company is a full-fledged service provider for cell biology, flowcytometry and proteomics. As envisioned by Felix, GeneX also acts as a middleman nurturing quality products, scientific and technical support between biotech solution providers in Europe, USA, UK and Indian researchers who work across the relevant fields.

GeneX India has an experienced team of 33 scientifically-qualified professionals who possess the capability to market, conduct workshops, seminars. They cumulatively provide solutions to scientists and research scholars, helping them complete their research. The team works in constant collaboration mode to ensure a zero-defect product and service range. The stringent quality standard and client-centric approach have made the enterprise synonymous to the word biotech all across the world.

Following this unprecedented rise, GeneX India has been recognized for its efforts via major accolades like the Biotech Excellence and the APJ Abdul Kalam Excellence Award. The CEO magazine also noted GeneX as one of the 25 fastest growing biotechnology companies in India recently. Moreover, Felix himself has been the recipient of multiple national and international awards such as the Mahatma Gandhi Samman at the House of Commons, UK.

Even during the COVID pandemic, Felix and his company have been dedicated to aiding ICMR approved testing labs and kit manufacturers. Vaccine research labs and producers are being helped in complete sync too.

As the future entails, Felix is now set on scaling the firm to global benchmarks and giving Indian research the world stage it deserves. A plan to support the bioprocess and vaccine development has been put in place as well. He also aims to produce affordable molecular diagnostic kits using the latest technology like the CRISPR Cas9 Genome editing tool. A Contract Research Lab that acts as a high-end core facility with its primary focus on Genomics and DNA sequencing for molecular diagnostics is also in the works. The end goal is to provide services to biotech researchers and in turn, become a parallel economic solution provider for the high throughput, time-bound turnkey biotech projects and diagnostic labs.

A reputable part of the significant science congresses across the country, Felix has always had the vision to create a sustainable future for the world. He has a strong conviction that the firms business model should make a profound and positive impact on the lives of all the researchers it touches. His every step has been towards building his own pathway that treads towards this purpose.

See more here:
Cell Biology, Molecular Biology, Biotechnology And The Man Who Is Connecting It All: Felix Paul Joe - Outlook India

Cell Biology

Molecular Biology of the Cell seeks early-career editors to focus on curating preprints – Newswise

Newswise Molecular Biology of the Cell (MBoC) is assembling an editorial board of early-career researchers dedicated to curating and classifying the impact of new articles published in MBoC and preprints posted on bioRxiv. Supported by a Learned Society Curation Awardfrom the Wellcome Trust and the Howard Hughes Medical Institute awarded to MBoCs publisher, the American Society for Cell Biology (ASCB), this new board of diverse, young editors will contribute to curation and recognition of research works across the subjects covered by MBoC.

The recent growth of preprint servers and rapid pace of research dissemination can pose a challenge for researchers and evaluators, says ASCB Curation Manager Michael Lacy. It is sometimes difficult to discover the most interesting articles to read or to assess the significance and potential impact of new research. Our curators will be a valuable addition to the journal and ASCBs community, helping to spotlight important work for a broader audience.

Early-career editors should meet the following criteria:

Responsibilities of early-career editors include:

Early-career editors receive:

Applications should be submitted by Monday January 18, 2021 and must include 1) a CV, 2) a brief description of their research topic, interest in the position and future career plans (1 page total), and 3) a letter of recommendation. We are especially interested in recruiting a diverse group of candidates including those from under-represented backgrounds, across international regions, and from a broad range of research topics.

For more information and instructions to apply, visit our web pageor contact Michael Lacy (mlacy@ascb.org)

Read more:
Molecular Biology of the Cell seeks early-career editors to focus on curating preprints - Newswise

Cell Biology

20 ways UM-Flint CAS innovated in 2020 (Part 1) – University of Michigan Flint News

It goes without saying: This year has been filled with unprecedented hardships. Students, faculty, and staff across the UM-Flint community have encountered countless challenges that often change from week to week.

Despite these challenges, UM-Flint remains committed to keeping students safe while continuing to provide a world-class education. UM-Flint has developed a culture of innovation to meet that goal. Solutions that were once hard to imagine are now embraced to help create the best experiences for students and community members.

This culture of innovation has spread to every school, college, and unit across the university, producing so many examples that they would be impossible to list in their entirety. This two-part series presents, in no particular order, 20 innovative highlights from the College of Arts & Sciences in 2020.

Students in AST 120: Survey of Astronomy, taught by Lecturer II Michele Stark, are learning by playing the video game "The University of Mars." While exploring the solar system, astronomy students discover more about elemental particles, moon phases, planetary orbits and more. It's easy to stay engaged with an online asynchronous course when you're having fun!

Assistant Professor of Biology You-shin Chen wanted to be sure her Cell Biology students got hands-on experience while studying from home. That's why she set up a drive-through on campus where students could pick up laboratory materials. Then they conducted numerous experiments away from the lab, including extracting DNA from fruits & vegetables and separating plant pigments to study photosynthesis. She says, "We are trying to be as a creative as possible to cultivate students' desire for learning."

After travel restrictions forced the Department of History to cancel their Wyatt Global Exploration Program, faculty began thinking of other ways they could support their students. That resulted in more than $70,000 in additional scholarships being awarded to every eligible History major and minor.

Performances from the Department of Theatre & Dance continued in new formats to keep students and audiences safe. The first performance of the season was Poof!, recorded in a socially distanced format and released online. In Poof!, a housewife comes to the end of her rope with an abusive husband, but she doesn't expect him to spontaneously combust.

The Department of Political Science didn't let remote learning stop Coffee & Conversation, an event series that invites the UM-Flint community to discuss current issues with faculty. On Nov. 11, they held a virtual election debrief, facilitating dialogue on the presidential election process. Many Political Science faculty have also contributed their expertise to media coverage of the election season; Lecturer IV Kim Saks-McManaway provided insight on election vote counts and Associate Professor Jason Kosnoski shed light on possible timelines for election results.

Our student chapter of the American Society of Mechanical Engineers designed, built, and tested an original drone design, in preparation for the national IAM3D competition. The pandemic forced the competition online, but they weren't deterred. The team developed a video showcasing their design process, earning them second place in just their second year competing.

In Shelley Spivack's CRJ 388/588: Corrections A Critical Perspective course, socially distanced learning has not stopped community leaders and working professionals from enhancing the experience for students. Among the guest speakers this year were Judge Mark Latchana of the 7th Circuit Court, Judge Jessica Hammon of 67th District Court, Leon El- Amin from the M.A.D.E. Institute, Dr. Denise Smith Allen, a retired state probation officer, and Chad Sharpe, Director of the Genesee Valley Regional Center.

36 high school teams competed in UM-Flint's High School Programming Competition, hosted by Computer Science & Information Systems. The event took place virtually in May despite the pandemic preventing in-person meetings. The high school competitors were treated to a keynote address from Dr. Mark Guzdial of UM-Ann Arbor.

Created by Assistant Professor of Biochemistry Besa Xhabija, the "Keeping COVID-19 Out of Flint" initiative provided both the protective equipment and knowledge necessary to help slow the spread of COVID-19. Xhabija collaborated with recent graduate Miguel Strawn to create informational videos and pamphlets. Miguel managed the delivery of 300 care packages containing masks, gloves, and soap to Flint Residents.

The 61,00 sq. ft. Expansion to the Murchie Science Building is on track to open in winter semester 2021. The MSB Expansion not only enhances the experience for STEM majorslearners in all disciplines will enjoy the benefits of a space that features a student-centered design that removes barriers to instruction.

Stay tuned for ten more innovations in part two of this series.

Go here to read the rest:
20 ways UM-Flint CAS innovated in 2020 (Part 1) - University of Michigan Flint News

Cell Biology

Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary – GlobeNewswire

Press Release

8 December 2020

Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary

Immunicum AB (publ; IMMU.ST) provided today an overview and details on the topics to be covered during the previously announced Investor Event regarding the proposed combination between Immunicum and DCprime. The live presentation and Q&A session will be led by members of the Immunicum and DCprime management teams during the webcast tomorrow, Wednesday, December 9th at 3.00 pm CET. To view the livestream of the event, click here: https://bit.ly/36V9VAQ

Questions can be sent before and during the event to ir@immunicum.com. The presentation is now available on Immunicums website.

The business combination with DCprime is a rare and exciting opportunity through which we gain improved control of the entire value chain of development for ilixadencel while adding a complementary clinical-stage program to our pipeline. This transaction is an essential step to generating shareholder value, commented Sven Rohmann, MD, Ph.D., CEO of Immunicum. Through this additional information and tomorrows Investor Event, our objective is to provide a more extensive overview of this proposed transaction to the Immunicum shareholders. Speaking for the combined leadership, we are convinced that this is a truly transformative opportunity for the Company.

Merger RationaleAs announced on November 18th, combining forces with DCprime will establish a leading company built on decades of combined immuno-oncology and cell therapy expertise in the field of allogeneic dendritic cell biology.

Building a Fully Integrated Company & Leveraging Value

Complementary Organizations & Clinical Pipeline

Broadening Shareholder Base & Financing

Transaction Process

Next Steps

Scientific BackgroundFrom a scientific perspective, both Immunicum and DCprime share the therapeutic approach of using allogeneic, off-the-shelf dendritic cell biology to enable a patients immune system to more effectively fight cancer.

Cancer Treatment in the Age of Immunotherapy

Dendritic Cells, Immunicum & DCprime

Clinical Pipeline UpdateThe combination of Immunicum and DCprime will enable the newly unified organization to advance a synergistic pipeline spanning both large and orphan indications in solid as well as blood-borne tumors, with two programs in Phase II clinical development and multiple near-term value inflection points as well as a portfolio of preclinical programs and research capabilities to fuel future pipeline expansion.

Combined Pipeline Overview & Upcoming Clinical Milestones

ASH Oral Presentation Update

Pipeline Expansion Opportunities

Transaction SummaryThe business combination of Immunicum and DCprime is first and foremost based on the shared and unique biology of allogeneic, off-the-shelf dendritic cell-based therapies and the complementary therapeutic approaches of intratumoral priming and cancer relapse vaccination. From this foundation, the unified company can build and expand a strong pipeline in solid and blood-borne tumors which will establish Immunicums position as a leading cell therapy player. This pipeline will also facilitate near- and long-term clinical development progress and value creation.

In addition, as two synergistic organizations, Immunicum and DCprime will bring together and further develop strong in-house research and process development capabilities.

Van Herk and AP4, two leading institutional investors, have expressed their support to the combined entity.

For more information, please contact:

Sven Rohmann, MD, Ph.D., CEOTelephone: +46 8 732 8400E-mail: info@immunicum.com

Investor Relations

Jonas Rodny and Carolin WikenPaues berg CommunicationsTelephone: +46 190 90 51 E-mail:ir@immunicum.com

Media Relations

Joanne Tudorica and Sophia Hergenhan, Ph.D.Trophic CommunicationsTelephone: +49 171 351 2733E-mail:ir@immunicum.com

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patients own immune system to fight cancer. The Companys lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. http://www.immunicum.com

Read the rest here:
Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary - GlobeNewswire